When I text you ? ?? it means we are going to take on Big Pharma and lower drug prices.
Welcome to the Week in Review.
1. Drug Pricing At The Center Of Reconciliation
We are on the verge of a massive win for patients. Yesterday, President Biden called on Congress to pass a reconciliation package with the drug price reforms currently in the Senate. With clear support from Senator Manchin and all other Senate Democrats, the drug pricing provisions have a path to passage once the parliamentarian finishes her review. These historic provisions would finally rein in prescription drug prices for American families, saving $288 billion over the next decade. “Let’s bring down prescription drug prices,” said Secretary Raimondo on ABC News. “If you put on the floor a bill that reduces prescription drug prices, we would be both reducing inflation and reducing one of the most painful monthly costs that face millions and millions of families,” Senator Chris Coons said. Center For American Progress put it well: “After decades of inaction, Congress cannot let this effort for reform come and go.” (Politico, Axios, ABC News, CAP)
2. Patients Are United: Affordable Drugs Now
A new survey shows overwhelming, bipartisan support for the prescription drug pricing policies proposed by the Senate – 7 out of ten voters support these historic provisions that include allowing Medicare to negotiate drug prices. Ulcerative colitis patient Kolton Chapman shared his experience struggling to balance chronic disease, paying for schooling, and the high prices of his prescription drugs. “I was going to have to pick between paying for my school or paying for my meds,” he shared with the Ohio Capital Journal. “And I need my meds to stay alive.” No one should have to choose between their health and their schooling. Patients like Kolton are counting on Congress to lower drug prices by passing the popular provisions in the reconciliation package now. (Morning Consult, Ohio Capital Journal)
3. Pharma Inflating Lies
A report published this week found that PhRMA and top pharmaceutical companies have spent $147.3 million lobbying Congress against lowering drug prices since 2020. We’re not surprised – Big Pharma is doubling down on its outrageous spending, as drug pricing reforms are closer than ever to passing. The industry continues to spread lies about the provisions, saying, “prescription drug prices are not contributing to inflation,” a false claim that relies on misleading data that bundles generic prices with brand-named prices. Don’t just take our word for it. Treasury Secretary Yellen remarked on Thursday that current Senate drug pricing reforms would lower “the cost of one of the most expensive items in [Americans’] budgets” and be a “very positive way of addressing inflation.” Americans aren’t fooled by pharma fear-mongering – we have our eye on the ball to lower drug prices and bring relief to American families by passing comprehensive reforms. (Common Dreams, P4ADNow)
Have a great weekend, everyone!
Welcome to the Week in Review.
1. Ready For Reconciling
In the greatest indication of momentum yet, Senate Democrats submitted the latest text of their comprehensive drug pricing reforms to the Senate Parliamentarian this week — the next step in its path to passage through reconciliation. The legislation, which is supported by all 50 Senate Democrats and over 80 percent of Americans, will deliver relief from high drug prices for millions of patients by allowing Medicare to negotiate directly for lower drug prices, curbing drug company price gouging, and capping out-of-pocket costs for Medicare Part D beneficiaries. The CBO found that the new legislation will save taxpayers over $287 billion over 10 years and again debunked one of Big Pharma’s favorite myths, finding the legislation would decrease the number of new drugs coming to market by under 1 percent — not the nuclear winter depicted by the drug industry. Patients know the truth: We can have the innovation we need at prices we can afford. There is no time to wait, the Senate needs to get it done now. (Punchbowl News)
2. AbbVie Up To No Good
A report from the Senate Finance Committee this week found that drug giant AbbVie has been gaming the system by charging high prices, bringing in record revenues, and then avoiding U.S. taxes. The report finds that the U.S. is responsible for 75 percent of the pharma company’s sales, yet AbbVie reported just one percent of that for the purposes of U.S. income taxes. Big Pharma’s main goal? Big profits. (Washington Post)
3. Raising Prices Because They Can
In a much welcomed collaboration, the U.S. Patent and Trademark Office (USPTO) and the Food and Drug Administration (FDA) are joining forcesto crack down on pharmaceutical companies’ manipulation of our patent system. Right now, corporations abuse the system in order to impede competition and keep prices high. The new effort is a result of President Biden’s 2021 executive order calling on the USPTO and FDA to collaborate on patent reforms that promote competition and encourage true innovation. Patent shenanigans by drug corporations have increased the price of some prescription medications by more than 300 percent— leaving patients struggling to afford their medications while pharma executives pad their bottom line. Patients are grateful for this much needed oversight. (USPTO, Mad In America)
Have a great weekend, everyone!
Welcome to the Week in Review.
1. The Way Forward Is Clear
In a major sign of renewed momentum for passing comprehensive drug pricing reform through reconciliation, Senate Democrats are moving to submit a drug pricing framework based on last year’s House-passed provisions to the Senate parliamentarian. If enacted, these historic reforms — which reportedly include Medicare negotiation, penalties on drug companies that raise prices faster than the rate of inflation, and an out-of-pocket cap for Medicare beneficiaries — would bring much-needed relief to patients across the country. “The way forward is clear; the momentum is strong,” said David Mitchell, a cancer patient and founder of P4ADNow. “The Senate must pass the package through reconciliation this summer.” Let’s get the job done. — (The Washington Post, The Hill, P4ADNow, Las Vegas Sun)
2. 8 In 10 Recommend: Medicare Negotiation
A new poll shows that allowing Medicare to negotiate lower drug prices is overwhelmingly popular among voters of all political stripes, with 8 in 10 saying they support the provision. Americans are sick and tired of sacrificing their financial well-being to pay the high prices of prescription drugs while pharma CEOs take home tens of millions of dollars each year. Voters are sending the message loud and clear: We need Congress to pass Medicare negotiation now. — (Data for Progress, P4AD)
3. Raising Prices Because They Can
The U.S. government bought 105 million more doses of Pfizer’s COVID-19 vaccine this week in a deal amounting to $3.2 billion. This time, however, Pfizer is raising prices on the life-saving vaccine — American taxpayers are paying over $30 per dose compared to the price of $19.50 per dose in early contracts. Analysts say the price increases for the government may suggest even higher prices for the vaccine when it enters the commercial market. A reminder: The mRNA vaccine, which has shattered sales records and brought in billions of dollars for Pfizer, is based on technology developed in taxpayer-funded laboratories. In the third year of a pandemic, one thing has remained consistent: Drug companies are more than willing to take advantage of patients and taxpayers to maximize the bottom line. — (Reuters, FiercePharma)
One more thing: Senator Warnock held a Senate Aging Committee field hearing on Friday that focused on lowering drug prices. At the hearing, Georgia patients and advocates shared how their struggle with high drug prices have cost them their financial and mental health. “We were in our golden years,” said retiree Gretchen Spring, “but the only people seeing gold were the pharmaceutical companies.”
Have a great weekend, everyone!
WASHINGTON, D.C. — The following statement was issued by David Mitchell, a cancer patient and founder of Patients For Affordable Drugs Now, in response to reports of Senate Democrats advancing historic, comprehensive drug pricing reforms:
“It is indeed good news for patients and all Americans that Senate Democrats are moving forward with a comprehensive plan to lower prescription drug prices. When enacted into law, these reforms will be historic. For the first time, Medicare will be able to negotiate lower drug prices directly with drug corporations, penalties will be imposed on companies that raise prices faster than the rate of inflation, and there will be an annual out-of-pocket cap for beneficiaries in Medicare Part D.
“Each of these changes will help bring relief from unrelenting high drug prices in the United States, which run almost four times what other nations pay for the same brand-name drugs. Americans — Republicans, Democrats, and independents alike — overwhelmingly support these reforms, and those in Congress who help get them across the finish line will be rewarded at the ballot box in November. The way forward is clear; the momentum is strong. The Senate must pass the package through reconciliation this summer. We will do everything in our power to help get the job done.”
###
Welcome to the Week in Review.
1. Keep Moving Full Steam Ahead
As talks between the White House and Senate Democrats progress, major drug pricing provisions, including Medicare negotiation, continue to be a top priority for inclusion in a reconciliation package. President Biden again told reporters this week that he believes Congress can pass reforms to lower drug prices. Secretary Yellen said, “We can bring down other costs that are burdening households like prescription drugs,” and National Economic Council Director Brian Deese said the White House is working closely with the Senate to move the reconciliation bill forward and is hopeful they can get the job done. But lawmakers must act quickly as the midterm elections draw nearer — time is running out to pass this legislation that will both lower prices for patients and save money for taxpayers. Senators, Americans are counting on you to deliver on your promises and get these reforms across the finish line. — (Bloomberg, The Hill, The Hill,The Post-Standard)
2. INSULIN Act: A Gift To Big Pharma
This week, Senators Shaheen and Collins unveiled a bill to lower insulin costs — an issue that has special poignancy for Americans, as 4 out of 5 adults who live with diabetes or are caregivers for someone with diabetes have gone into debt to pay for insulin. However, the legislation only addresses insulin copays without guaranteeing lower list prices, which will result in cost-shifting and lead to higher premiums and taxes. Make no mistake: This bill is a capitulation to Big Pharma that allows drug makers to continue hiking insulin prices while leaving patients with less money in our pockets. If senators are serious about helping patients, they must pass the package of comprehensive drug pricing reforms, including capping insulin copays to $35 and historic provisions such as Medicare negotiation, through reconciliation. — (Roll Call, P4ADNow)
3. Pharma’s Up To No Good
Pharma’s shady behavior has been in the spotlight this month. Throughout June, P4AD has been highlightingsomeofthedrug companies with the highest 2021 revenues and how they repeatedly price gouge patients to maximize their profits. A new OpenSecrets report also details the deluge of recent pharma lobbying spending. Just last year, the drug industry groups spent over $350 million lobbying at the federal level and tens of millions more in state capitols — all to keep prices high and continue filling their coffers at the expense of patients. — (P4AD, OpenSecrets)
“The bipartisan effort by Senators Shaheen and Collins is further evidence of the power of the drug pricing issue for voters of all political persuasions — Democrats, Republicans, and independents alike. Members of Congress understand that Americans want action to lower drug prices — and insulin has special poignancy.
“People with diabetes are at the mercy of unjustly high insulin prices, and a $35 copay cap would deliver relief to those with insurance. Four out of five adults who live with diabetes or are caregivers for someone with diabetes have gone into debt to pay for insulin.
“But this legislative text does not guarantee lower list prices for insulin, without which copay caps will result in cost-shifting for insulin and lead to higher premiums and taxes. Without lowering list prices, the insulin copay caps are estimated to cost more than $20 billion over 10 years, according to a Congressional Budget Office score of the insulin copay cap bill passed by the House of Representatives. It is difficult to imagine insulin makers will voluntarily reduce their net prices. History tells us we cannot rely on pharma to do the right thing, and this bill does not offer any enforcement.
“Conversely, Senate Democrats have a unique opportunity right now to pass comprehensive legislation that would both cap insulin copays and lower the list price of insulin and other critical drugs. The drug price provisions passed by the House and under consideration by the Senate will cap insulin copays to $35, prevent drug corporations from price gouging patients with year-over-year increases, and finally allow Medicare to negotiate directly with drug companies for lower prices on prescription drugs, including insulin.
“There are millions of patients who rely on expensive medications who urgently need the reforms in the drug pricing package, including, most importantly, Medicare negotiation. There is a path forward in the Senate to pass the legislation through reconciliation. President Biden believes the votes are there to pass drug pricing reform, Speaker Pelosi expressed optimism for the reconciliation bill, Senator Manchin and Majority Leader Schumer’s negotiations on reconciliation have resumed, and Senator Manchin remains committed to passing comprehensive drug pricing reforms.
“In order to deliver on their promises to all patients — including those who depend on insulin — the Senate’s number one priority on drug pricing must be to pass the broad drug price provisions through reconciliation.”
###
Who knows if the rumors are true about BTS breaking up? But what we do know is that we WILL break up Big Pharma’s monopoly pricing power.
Welcome to the Week in Review.
1. Reconciliation: It’s Alive!
The momentum to pass a reconciliation bill with drug pricing reforms is building as talks between Leader Schumer and Senator Manchin have progressed, with the majority leader’s staff reportedly taking the next steps to line up a vote for later this summer. President Biden said he believes the votes are there to pass drug pricing reform in an AP interview, and Speaker Pelosi also expressed optimism for the reconciliation bill, saying, “It’s alive.” Meanwhile, patients, advocates, and physicianswrote opinion pieces this week urging Congress to act quickly to lower drug prices. “It’s unfair that patients like me have to shell out thousands of dollars just to stay alive. We deserve better,” shares Bob Parant, a New York patient who lives with type 1 diabetes. “Policymakers face a choice: let prescription drug costs continue to rise unchecked, placing patients and families at continued risk, or pass sensible reforms that would make drugs more affordable for all Americans,” four doctors write. — (Politico, AP, New York Daily News, The Exponent-Telegram, The Hill, MedPage Today, The Philadelphia Inquirer)
2. Three Pinocchios For Pharma Front Group ? ? ?
A new fact check from The Washington Post debunks an ad from the pharma front group 60 Plus Association that dishonestly characterizes the drug pricing reforms before the Senate as a plan that would “strip $300 billion from Medicare” and leave patients with “fewer treatments and cures.” The truth? According to the nonpartisan Congressional Budget Office’s analysis, the reforms will save taxpayers and the federal government $300 billion while only reducing the number of new drugs coming to market by 0.8 percent over the next 30 years. In a desperate move to maintain the industry’s unfettered pricing power, pharma-allied groups are filling the airwaves with lies. Americans know better. — (The Washington Post)
3. Pulling Back The Curtain On Blood Thinners
In a letter to the Federal Trade Commission this week, Senator Klobuchar and Rep. Porter called on the agency to investigate the lockstep price hikes on the blood thinners Eliquis and Xarelto and whether they constitute a violation of antitrust laws. Eliquis and Xarelto, manufactured by BMS/Pfizer and Johnson & Johnson, respectively, were the subjects of a recent P4AD report examining how the systematic price increases and patent gaming on these drugs hurt patients and raise costs for taxpayers. We applaud the senator and representative for taking on the pharmaceutical industry and fighting on behalf of patients. — (FiercePharma)
4. More Wins For Patients!
On Tuesday, the Senate Committee on Health, Education, Labor, and Pensions passed an FDA bill that included three amendments to boost competition in the drug pricing system by easing the process for generic competition to come to market. One of the amendments, based on legislation P4ADNow has been advocating for since 2018, would close a loophole in the citizen petition process that brand-name drug makers have exploited to slow the approval of lower-priced generics to keep prices high. We thank Senators Murray, Baldwin, Hassan, and Paul for championing these amendments and urge the full Senate to pass this package with the citizen petition, orphan drug, and generic drug approval transparency reforms intact. — (P4ADNow)
5. Eyes On PBMs
The FTC is setting its sights on the byzantine practices of pharmacy benefit managers. On Thursday, the commission voted to study PBMs’ usage of rebates to determine if the system contributes to an anticompetitive prescription drug market that keeps prices high, and specifically pointed to insulin as a drug that has experienced soaring prices in part due to rebates paid to PBMs. This vote comes as a whistleblower suit alleges that CVS used its subsidiaries, including its PBM, Caremark, to push patients toward brand-name medications instead of cheaper generics in order to obtain higher rebates. The FTC’s decision to shine a light on these corporations and inject more transparency into the drug system is another welcome move for patients. — (Reuters, Endpoints News, FiercePharma)
One more thing: A new Gallup poll reveals that about 17 million Americans over 50 years old said they or a family member have not taken medication as prescribed to save money in the past year.
Have a great weekend, everyone!
WASHINGTON, D.C. — The following statement was issued by David Mitchell, a cancer patient and founder of Patients For Affordable Drugs Now, in response to the Senate Health, Education, Labor, and Pensions Committee’s passage of a package that includes three amendments that would crack down on Big Pharma’s abuses of the drug pricing system:
“We applaud Chairwoman Murray, ranking member Burr, and members of the Senate HELP Committee for advancing S. 4348, which reauthorizes the FDA user fees and includes three key amendments to improve the U.S. drug pricing system to boost competition by easing the process for generic competition to come to market and drive down drug prices for patients. The bipartisan citizen petition provision, offered by Senator Baldwin (D-WI) and championed by Senators Shaheen (D-NH), Cassidy (R-LA), Bennet (D-CO), and Rubio (R-FL), will help restore integrity to the FDA citizen petition process by closing a loophole manipulated and abused by brand-name drug makers to slow the approval of lower-priced generics and keep prices high for patients.
“For years, the P4ADNow patient community has been calling on Congress to pass legislation to prevent Big Pharma from using the citizen petition process to delay or block more affordable generic drugs from coming to market. On behalf of patients across the country, we thank Senators Baldwin, Shaheen, Cassidy, Bennet, and Rubio for their work fighting for patients.
“We urge the Senate to quickly pass the FDA user fee package with the citizen petition, orphan drug, and generic drug approval transparency reforms intact.
“The committee’s approval of these provisions adds important momentum to the work being done in the Senate to pass a reconciliation package that includes the comprehensive drug price reforms, including Medicare negotiation, already passed by the House of Representatives. The Senate must advance the reconciliation package to deliver relief to all American patients.”
###
Background:
P4ADNow has been advocating tirelessly since 2018,urging the federal government and Congress to address pharmaceutical companies’ abuse of the Food and Drug Administration’s citizen petition process.
The amendment, introduced by Senator Baldwin (D-WI) to crack down on abuse of the citizen petition process, has been previously introduced in the Senate as S. 562, the Ensuring Timely Access to Generics Act, which was sponsored by Senators Shaheen (D-NH), Cassidy (R-LA), Bennet (D-CO), and Rubio (R-FL).
The FDA’s 505(q) citizen petition process is intended to provide a forum for patients, consumer groups, and other entities to raise concerns about pending generic drug approvals under consideration by the FDA.
Currently, the citizen petition process is often misused by brand-name drug manufacturers that submit sham petitions in an effort to delay or block generic approval and market entry.
Brand-name drug makers were behind 92 percent of all 505(q) citizen petitions filed between 2011 and 2015.
This bill would strengthen the citizen petition process, more effectively weeding out petitions that are filed with the intent to delay the approval of generics or biosimilars.
The Senate HELP committee also included in S. 4348 the RARE Act (S. 4185), offered as an amendment by Senator Baldwin and sponsored by Senators Baldwin and Cassidy. The bill codifies FDA’s longstanding interpretation of the Orphan Drug Act and prevents drug makers from taking advantage of a 2021 circuit court decision that would enable them to block competitors. The House passed a similar provision in the chamber’s user fee package last week.
The Senate HELP committee also advanced a bipartisan amendment, led by Senators Hassan (D-NH) and Paul (R-KY), that would speed more affordable generic drugs to market by giving the FDA the authority to provide specific information on inactive ingredients and drug concentration levels to generic applicants working to come to market. The House passed a similar provision in the chamber’s user fee package last week.
